Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer.

Clicks: 316
ID: 43770
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Propagermanium (PG) inhibits the CCL2/CCR2 axis, and has been shown to function as an immune modulator. This study investigated its anti-tumor mechanism in patients with refractory cancers.Five healthy volunteers and 23 patients with refractory oral (n=8) or gastric (n=15) cancer received PG (30 mg/day). We performed flow cytometry (FCM) of peripheral blood mononuclear cells and in vitro killing assays.FCM revealed that CD16/CD56 NK cells (i.e., mature, cytolytic subset) increased, and the apoptosis induction rate of cancer cells increased after PG administration. Among gastric cancer patients, median OS was 172.0 days. Two patients showed complete remission of lung or liver metastasis. Survival of patients with oral cancer also tended to be prolonged.PG induces NK cell maturation, and may potentiate anti-tumor activity.
Reference Key
kikuchi2019propagermaniumanticancer Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kikuchi, Shojiro;Noguchi, Kazuma;Wakai, Keiko;Hamazaki, Yoko;Tozawa, Katsuyuki;Jomori, Takahito;Sasako, Mitsuru;Miwa, Hiroto;
Journal Anticancer research
Year 2019
DOI 10.21873/anticanres.13651
URL
Keywords
maturation oral cancer gastric cancer nk cells propagermanium

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.